Bicycle and CRUK to launch first clinical trial of bicyclic peptide for use in treating tumours
Bicycle Therapeutics and Cancer Research UK have commenced the first clinical study to assess a bicyclic peptide to evaluate its potential in patients with advanced solid tumours. The first patient has now been dosed in a Phase I/IIa trial with BT1718, a first-in-class Bicycle Toxin Conjugate that targets Membrane Type 1 Matrix Metalloproteinase, which is